Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030567 (Parkinson's disease)
 63,064 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Inconsistencies within results of case-control studies on Alzheimer's disease risk factors led to a search of the literature for a potential cofactor. Reduced cerebral blood flow was selected and literature was surveyed for evidence of a cerebral blood flow linkage with the more than 40 putative risks. Alcohol abuse, depression, head trauma, underactivity, old age, sleep disturbance, glucose utilization, Down's syndrome, and Parkinson's disease are risk factors where an association with reduced cerebral blood flow is documented. Studies were cited showing that improved cerebral blood flow is associated with factors thought to be helpful in Alzheimer's disease, such as education or occupational attainment, exercise, headache, smoking, and arthritis/anti-inflammatory drugs to the extent that aspirin is used. Sugar consumption is identified as a potential risk factor with glucose management in Alzheimer's disease also shown to involve reduced cerebral blood flow. An hypothesis is developed showing how compromised regional cerebral blood flow could fit as a cofactor for genetic, autoimmune, and neurotoxic aspects of Alzheimer's disease.
 ...
PMID:Alzheimer's disease risk factors as related to cerebral blood flow. 873 67

Neuropsychological and motor deficits in Parkinson's disease that may contribute to driving impairment were examined in a cohort study comparing patients with Parkinson's disease (PD) to patients with Alzheimer's disease (AD) and to healthy elderly controls. Nondemented individuals with Parkinson's disease [Hoehn & Yahr (H&Y) stage I-III], patients with Alzheimer's disease [Clinical Demetia Rating scale (CDR) range 0-1], and elderly controls, who were actively driving, completed a neuropsychological battery and a standardized road test administered by a professional driving instructor. On-road driving ability was rated on number of driving errors and a global rating of safe, marginal, or unsafe. Overall, Alzheimer's patients were more impaired drivers than Parkinson's patients. Parkinson's patients distinguished themselves from other drivers by a head-turning deficiency. Drivers with neuropsychological impairment were more likely to be unsafe drivers in both disease groups compared to controls. Compared to controls, unsafe drivers with Alzheimer's disease were impaired across all neuropsychological measures except finger tapping. Driving performance in Parkinson's patients was related to disease severity (H&Y), neuropsychological measures [Rey Osterreith Complex Figure (ROCF), Trails B, Hopkins Verbal List Learning Test (HVLT)-delay], and specific motor symptoms (axial rigidity, postural instability), but not to the Unified Parkinson Disease Rating Scale (UPDRS) motor score. Multifactorial measures (ROCF, Trails B) were useful in distinguishing safe from unsafe drivers in both patient groups.
 ...
PMID:Neuropsychological deficits associated with driving performance in Parkinson's and Alzheimer's disease. 1624 12

The aim of this study was to evaluate the brain scintiscan images with (123)I-ioflupane for the diagnosis of patients with early Parkinson's disease (PD). Sixteen patients were studied, nine males and seven females, aged between 38-81 y (mean age: 64 y). All patients underwent thyroid blocking by oral administration of 120 mg potassium iodide before and 24 h after the intravenous (iv) injection of 110-185 MBq/70 kg patient's weight, of (123)I-ioflupane. To check the correct biodistribution of the radiopharmaceutical, whole-body scans were performed at 15 min and 2-3 h after the administration of the radiopharmaceutical. All patients underwent brain single photon emission tomography (SPET) scans on a SPET gamma-camera 3-5 h after (123)I-ioflupane administration. To compensate for scatter and to avoid artifacts, the filtering and reconstructing procedures of the images were performed individually for each patient. Brain SPET results were evaluated semi-quantitatively using different indices. The morphology of the nigrostriatum (NS) area was also examined visually. The (123)I-ioflupane uptake by the affected nigrostriatum (ANS) was compared to a similar area at the occipital (Occ) brain section and to a similar area at the opposite NS. When the value of ANS/Occ was within the confidence limit of 1.507-1.636 and the value of ANS/NNS was within the limit of 0.755-0.889, PD was diagnosed (P<0.05). Thirteen of our patients were diagnosed as having PD and were given l-DOPA treatment. In the remaining patients the diagnosis of PD was rejected due to normal scintigraphic and morphologic findings of the NS area. The interest of this article lies in the following: The correct distribution of the radiopharmaceutical was confirmed by whole body scintiscan. Parameters for better quality of imaging were individually selected for each patient. The morphology of the NS areas, as estimated visually by us, was in accord with the scintigraphic (123)I-ioflupane uptake. The diagnosis of PD was clinically confirmed after treatment with l-DOPA in a seven month follow up period. Results from the small number of cases studied showed: 93% sensitivity and maximum specificity for the diagnosis of PD.
Hell J Nucl Med
PMID:The brain scintiscan with iodine-123-ioflupane to diagnose early Parkinson's disease; seven months follow up. First results in Bulgaria. 1661 91

State-of-the-art radioactive drug development has become a helpful tool in new functional imaging technologies in neurosciences. Drug development programs are evaluated in terms of effective biodistribution, costs and time. This article details the existing drug development parameters for neuroimaging and highlights some examples, as in Parkinson's disease, alcoholic neuritis and psychotic diseases, showing the benefit and the potential of using new functional neuroimaging technologies for specific studies of the central nervous system.
Hell J Nucl Med
PMID:Drug development parameters for functional imaging in neurosciences. 1768 81

In this article, an account is given on the author's experience with auditory based neuropsychology in a clinical, neurosurgical setting. The patients that were included in the studies are patients with traumatic or vascular brain lesions, patients undergoing brain surgery to alleviate symptoms of Parkinson's disease, or patients harbouring an intracranial arachnoid cyst affecting the temporal or the frontal lobe. The aims of these investigations were to collect information about the location of cognitive processes in the human brain, or to disclose dyscognition in patients with an arachnoid cyst. All the patients were tested with the DL technique. In addition, the cyst patients were subjected to a number of non-auditory, standard neuropsychological tests, such as Benton Visual Retention Test, Street Gestalt Test, Stroop Test and Trails Test A and B. The neuropsychological tests revealed that arachnoid cysts in general cause dyscognition that also includes auditory processes, and more importantly, that these cognition deficits normalise after surgical removal of the cyst. These observations constitute strong evidence in favour of surgical decompression.
 ...
PMID:Auditory based neuropsychology in neurosurgery. 1802 27

The accumulation of filamentous alpha-synuclein (alpha-S) is associated with Parkinson's disease. It remains controversial as to the mode (antiparallel or parallel) of alpha-S self-assembly and whether an exact alignment of the central hydrophobic region is essential. In the present study, we performed in vitro assembly using alpha-S with or without the attachment of artificial leucine zippers (Zips) capable of forming either parallel or antiparallel coiled coils and included a spacer in one derivative. Results showed that Zips accelerate filament assembly in both the parallel and antiparallel fashions, that a precise alignment of the central hydrophobic region is not essential, and that the antiparallel pairs displayed the highest thioflavin T signals. More importantly, cells expressing Zip-fused alpha-S, but not alpha-S alone, formed alpha-S immunopositive and thioflavin S-positive inclusions in 7 days. The results suggest that alpha-S can assemble in both parallel and antiparallel modes but have a higher tendency to assemble in the latter mode and that cells overexpressing Zip-fused alpha-S may be used to screen alpha-S assembly inhibitors due to enhanced ability to form inclusions.
 ...
PMID:Using leucine zipper to facilitate alpha-synuclein assembly. 1849 24

Autosomal dominant familial Parkinson's disease (PD) due to the alpha-synuclein (G209A) mutation shares similar clinical characteristics with sporadic PD. Pathological studies however indicate more widespread neuronal degeneration in the familial form. We performed (123)I-FP-CIT SPET (DaTSCAN) study in nine patients with familial PD carrying the alpha-synuclein (G209A) mutation and fifteen matched patients with sporadic disease. Both groups had equal radioligand reduction uptake in the striatum but the alpha-synuclein patients showed less asymmetry and increased putamen to caudate ratio. Our findings indicate that there are minor differences in DAT SPET parameters between alpha-synuclein and sporadic PD patients insufficient to provide differential diagnosis.
Hell J Nucl Med
PMID:(123)I-FP-CIT SPET striatal uptake in parkinsonian patients with the alpha-synuclein (G209A) mutation A. 1908 58

Cocktail recipes containing Psoralea corylifolia seeds (PCS) are used to empirically treat Parkinson disease. A PCS isolate Delta(3),2-hydroxybakuchiol (BU) can inhibit dopamine uptake in dopamine transporter (DAT) transfected Chinese hamster ovary (CHO) cells, and dopamine reuptake blockade may provide an alternative approach for ameliorating parkinsonism. Here, we assessed the potential dopaminergic neuroprotective, and antiparkinsonian-like activity of BU. BU sample size was increased by using a scale-up extraction paradigm. Pharmacologically, BU significantly protected SK-N-SH cells from 1-methyl-4-phenylpyridinium (MPP(+)) insult, produced striking inhibitory actions on dopamine/norepinephrine uptake and WIN35,428 binding in synaptosomes on in vivo administration, and significantly preventing poor performance on rotarod and dopaminergic loss in substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mice. BU acts by protecting dopaminergic neurons from MPP(+) injury and preventing against MPTP-induced behavioral and histological lesions in the Parkinson's disease (PD) model, possibly by inhibiting monoamine transporters. These findings suggest that BU could be meaningful in PD treatment.
 ...
PMID:In vitro dopaminergic neuroprotective and in vivo antiparkinsonian-like effects of Delta 3,2-hydroxybakuchiol isolated from Psoralea corylifolia (L.). 1932 17

This study compared patterns of frontal-lobe dysfunction in alcoholics with Korsakoff's syndrome (KS: n = 9), non-Korsakoff alcoholics (AL: n = 28), patients with Parkinson's disease (PD: n = 18), and patients with rupture and repair of the anterior communicating artery (ACoA: n = 4) relative to healthy non-neurological control (NC) participants (n = 70). The tests administered were sensitive to functions of dorsolateral prefrontal and orbito-frontal subsystems. Measures included perseverative errors on the Wisconsin Card Sorting Test (WCST-pe), errors on object alternation (OA), errors on Trails B, number of words generated on the Controlled Oral Word Association Test (COWAT), and number of categories completed on the WCST (WCST-cc). KS patients were as impaired as AL participants on orbitofrontal measures and, on dorsolateral prefrontal measures, were impaired relative to AL participants, whose performance did not differ from controls. Patients with PD also were impaired on tests of orbitofrontal and dorsolateral prefrontal functioning but to a lesser extent than the KS patients. Moreover, most of the PD deficits were driven by the impaired performance of patients whose initial symptoms were on the right side of the body. The ACoA patients were significantly impaired on tests of orbitofrontal but not dorsolateral prefrontal functioning relative to the control group. Together, the results confirm different patterns of frontal-system impairments in patient groups having compromised frontal lobe functioning consequent to varying etiologies.
 ...
PMID:Patterns of prefrontal dysfunction in alcoholics with and without Korsakoff's syndrome, patients with Parkinson's disease, and patients with rupture and repair of the anterior communicating artery. 1941 79

Limited clinical information has been published on cases pathologically diagnosed with incidental Lewy body disease (ILBD). Standardized, longitudinal movement and cognitive data was collected on a cohort of subjects enrolled in the Sun Health Research Institute Brain and Body Donation Program. Of 277 autopsied subjects who had antemortem clinical evaluations within the previous 3 years, 76 did not have Parkinson's disease, a related disorder, or dementia of which 15 (20%) had ILBD. Minor extrapyramidal signs were common in subjects with and without ILBD. Cognitive testing revealed an abnormality in the ILBD group in the Trails B test only. ILBD cases had olfactory dysfunction; however, sample size was very small. This preliminary report revealed ILBD cases have movement and cognitive findings that for the most part were not out of proportion to similarly assessed and age-similar cases without Lewy bodies. Larger sample size is needed to have the power to better assess group differences.
 ...
PMID:Incidental Lewy body disease: clinical comparison to a control cohort. 2017 11


1 2 3 Next >>